Alector, Inc. (ALEC)

NASDAQ: ALEC · IEX Real-Time Price · USD
7.41
+0.44 (6.31%)
At close: Mar 1, 2024, 4:00 PM
7.58
+0.17 (2.29%)
After-hours: Mar 1, 2024, 7:31 PM EST
6.31%
Market Cap 709.50M
Revenue (ttm) 97.06M
Net Income (ttm) -130.39M
Shares Out 95.01M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE 526.32
Dividend n/a
Ex-Dividend Date n/a
Volume 1,639,623
Open 7.05
Previous Close 6.97
Day's Range 7.05 - 7.57
52-Week Range 3.66 - 9.07
Beta 0.77
Analysts Buy
Price Target 14.67 (+97.98%)
Earnings Date Feb 27, 2024

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The compa... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2019
Employees 244
Stock Exchange NASDAQ
Ticker Symbol ALEC
Full Company Profile

Financial Performance

In 2023, Alector's revenue was $97.06 million, a decrease of -27.36% compared to the previous year's $133.62 million. Losses were -$130.39 million, -2.19% less than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 97.98% from the latest price.

Price Target
$14.67
(97.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will pa...

4 days ago - GlobeNewsWire

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023

5 days ago - GlobeNewsWire

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

12 days ago - GlobeNewsWire

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 28...

24 days ago - GlobeNewsWire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the...

25 days ago - GlobeNewsWire

Alector Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its unde...

6 weeks ago - GlobeNewsWire

Alector Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an under...

6 weeks ago - GlobeNewsWire

Alector Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offe...

6 weeks ago - GlobeNewsWire

These biotechs targeting multiple neurodegenerative diseases

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive...

Other symbols: ABBVAMLXATHACOYAGSK
3 months ago - MarketBeat

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to p...

3 months ago - GlobeNewsWire

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...

4 months ago - GlobeNewsWire

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants

4 months ago - GlobeNewsWire

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pion...

4 months ago - GlobeNewsWire

Alector to Host Mid-Year Earnings Conference Call

Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT

7 months ago - GlobeNewsWire

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...

9 months ago - GlobeNewsWire

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025

10 months ago - GlobeNewsWire

Alector to Participate in the BofA Securities 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will particip...

10 months ago - GlobeNewsWire

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer's disease in Q3 2023, with data readout expected by Q4 2024

1 year ago - GlobeNewsWire

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announ...

1 year ago - GlobeNewsWire

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer's disease

1 year ago - GlobeNewsWire

Alector Announces Promotion of Clare Hunt to Chief People Officer

Promotion demonstrates Alector's commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees

1 year ago - GlobeNewsWire

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD

1 year ago - GlobeNewsWire

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...

1 year ago - GlobeNewsWire

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation co...

1 year ago - GlobeNewsWire

Alector to Participate at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will particip...

1 year ago - GlobeNewsWire